Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine Phase 3 Study in Moderate to Severe COPD
NCT05743075Phase 3Completed
- Sponsor
- Nuance Pharma
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Nuance Pharma. Started Mar 2023; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05743075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743075.